Agenus Inc. a biopharmaceutical company focused on immuno-oncology, is at the forefront of innovation aimed at improving treatment responses for colorectal cancer. The Lexington, Massachusetts-based company recently announced its participation in the B. Riley Securities Precision Oncology & Radiopharma Investor Conference, scheduled for February 28, 2025, in New York. During this event, Robin Taylor, Ph.D. the Chief Commercial Officer of Agenus, will partake in a panel discussion
Agenus Inc. Pioneering Advances in Colorectal Cancer Immunotherapy Amid Financial and Strategic Developments
Published |
Modified
CSIMarket Newsroom | CSIMarket.com
CSIMarket Newsroom | CSIMarket.com
Sources for this article: Based on Agenus Inc’s official statement and Competitive Environment Analysis by CSIMarket.com
For details on how CSIMarket validates financial and corporate news, please review our
Editorial Standards & Fact-Checking Policy
.
Comments